HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bloomgarden, Z. T. Search for Related Content PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

Second World Congress on the Insulin Resistance Syndrome

Hypertension, cardiovascular disease, and treatment approaches

Abbreviations: apoB, apolipoprotein B • ARB, angiotensin II receptor blocker • ATP, Adult Treatment Panel • CPAP, continuous positive airways pressure • CRP, C-reactive protein • CVD, cardiovascular disease • DPP, Diabetes Prevention Program • DREAM, Diabetes Reduction Assessment with ramipril and rosiglitazone Medication • EDS, excessive daytime sleepiness • FDA, Food and Drug Administration • FFA, free fatty acid • IGT, impaired glucose tolerance • IL, interleukin • LPL, lipoprotein lipase • PCOS, polycystic ovarian syndrome • PPAR, peroxisome proliferator–activated receptor • RAS, renin-angiotensin system • TZD, thiazolidinedione • VA-HIT, Veterans Affairs HDL Intervention Trial

The first 300 words of the full text of this article appear below.

This is the third and final installment in a series of articles on the Second World Congress on the Insulin Resistance Syndrome, Universal City, California, 18–20 November 2004.

Insulin resistance and hypertension

At a symposium on insulin resistance, hypertension, and cardiovascular disease (CVD) cosponsored by the European Group for the Research of Obesity, Hypertension, and Insulin Resistance, Albert P. Rocchini (Ann Arbor, MI) discussed the relationship of hypertension and insulin resistance in obesity. Potential explanations for the frequency with which insulin resistance and hypertension are associated could be the coincidence of two common abnormalities, the causation of one by the other, or, intriguingly, the existence of a common underlying factor. The first explanation appears unlikely, with a preponderance of evidence suggesting that the two conditions are related (1). It also appears unlikely that hypertension causes insulin resistance, as glucose uptake is not affected in experimental renovascular hypertension and because lowering blood pressure in individuals with hypertension does not necessarily improve glucose uptake. There is, however, greater forearm vascular resistance in obese than in nonobese adolescents, with glucose uptake across this tissue inversely related to vascular resistance, suggesting that vascular resistance may play a role in some aspects of insulin action (2). The converse, that insulin resistance may cause hypertension, appears more likely to be a factor. Fasting insulin levels correlate with systolic blood pressure, and the drop in blood pressure following weight loss is related to the improvement in insulin sensitivity. Interestingly, in hypertensive obese individuals, somatostatin decreases both the insulin level and blood pressure, suggesting an effect of hyperinsulinemia. Insulin can lead to sodium retention (3) and angiotensin II–mediated aldosterone production, can change vascular structure and function, can alter cation flux, and can activate the sympathetic nervous system. In both obese and nonobese individuals during water diuresis, . . . [Full Text of this Article]

Insulin resistance, dyslipidemia, and heart disease

Treatment of the insulin resistance syndrome

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?